C. Nerl

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Rüdiger Hehlmann, Michael Lauseker, Susanne Saußele et al. · Leukemia · 2017 · 339 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: Prognostic impact of clinical observations and laboratory findings at presentation

W. Siegert, C. Nerl, Alexander G Agthe et al. · Annals of Oncology · 1995 · 131 citations · Full text

Medicine, Hematology, Oncology +17

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C

Martin C. Müller, Norbert Gattermann, Tanja Lahaye et al. · Leukemia · 2003 · 126 citations

Medicine, Hematology, Oncology +12

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

Manuel Barreto Miranda, Michael Lauseker, M-P Kraus et al. · Leukemia · 2016 · 88 citations · Full text

Medicine, Oncology, Pharmacology +10

Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon α and hydroxyurea

Rüdiger Hehlmann, Ute Berger, Markus Pfirrmann et al. · Leukemia · 2003 · 81 citations

Pharmacy, Oncology, Pharmacotherapy +7